Open AccessP776: A PHASE 2, OPEN‐LABEL, ASCENDING DOSE STUDY OF KER‐050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES
Author(s) -
Tan S.,
Arbelaez A.,
Chee L.,
Fong C. Y.,
Hiwase D.,
Kannourakis G.,
Kwan J.,
Liang J.,
Puliyayil A.,
Rose H.,
Ross D.,
Teh T.C.,
Westerman D.,
Wight J.,
Feng W.,
Lachey J.,
McGinty A.,
Natarajan H.,
Rovaldi C.,
Cooper S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845988.37454.e6
Subject(s) - medicine , tolerability , discontinuation , anemia , international prognostic scoring system , myelodysplastic syndromes , erythropoiesis , adverse effect , bone marrow